News articles about ArQule (NASDAQ:ARQL) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. ArQule earned a news sentiment score of 0.05 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.3781863395155 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
ArQule (NASDAQ:ARQL) traded up $0.09 during trading hours on Friday, hitting $1.72. The company’s stock had a trading volume of 197,163 shares, compared to its average volume of 182,144. The firm has a market cap of $158.10, a price-to-earnings ratio of -4.30 and a beta of 1.48. ArQule has a 52-week low of $0.92 and a 52-week high of $1.98. The company has a debt-to-equity ratio of 2.33, a current ratio of 3.45 and a quick ratio of 3.45.
ARQL has been the topic of several recent analyst reports. B. Riley initiated coverage on ArQule in a research report on Friday, February 2nd. They set a “buy” rating and a $3.00 price target on the stock. Zacks Investment Research lowered ArQule from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. ValuEngine raised ArQule from a “strong sell” rating to a “sell” rating in a research report on Friday, November 17th. Finally, Needham & Company LLC raised ArQule from a “hold” rating to a “buy” rating in a research report on Thursday, December 14th.
ILLEGAL ACTIVITY NOTICE: “ArQule (ARQL) Earning Somewhat Favorable Media Coverage, Analysis Shows” was first reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2018/02/17/arqule-arql-earning-somewhat-favorable-media-coverage-analysis-shows.html.
ArQule Company Profile
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.